BNGO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

7.93M

-2.86%

-1.360

-82.41%

8.37M

+29.66%

-0.780

-32.17%

9.08M

+34.78%

-0.740

-62.81%

Estimates Revision

The market is revising Upward the revenue expectations for Bionano Genomics, Inc. (BNGO) for FY2025, with the revenue forecasts being adjusted by 0.12% over the past three months. During the same period, the stock price has changed by -18.97%.

Revenue Estimates for FY2025

Revise Upward

+0.12%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-17.94%

In Past 3 Month

Stock Price

Go Down

-18.97%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast BNGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNGO is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

H.C. Wainwright

Buy

downgrade

$11 -> $7

2025-11-24

Reason

H.C. Wainwright

Price Target

$11 -> $7

2025-11-24

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Bionano Genomics to $7 from $11 and keeps a Buy rating on the shares. The firm adjusted the company's model post the Q3 report.

H.C. Wainwright

Buy

maintain

$10 -> $11

2025-08-18

Reason

H.C. Wainwright

Price Target

$10 -> $11

2025-08-18

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Bionano Genomics to $11 from $10 and keeps a Buy rating on the shares. The company demonstrated sequential revenue growth in Q2, the analyst tells investors in a research note.

Maxim

Jason McCarthy

Hold

Buy

upgrade

2025-05-20

Reason

Maxim

Jason McCarthy

Price Target

2025-05-20

upgrade

Hold

Buy

Reason

Maxim analyst Jason McCarthy upgraded Bionano Genomics to Buy from Hold with an $8 price target. The company has taken several steps to get itself back on track, including significant cost reductions, refocusing on its core optical genome mapping business, shifting focus from customer acquisition to expanding utilization, and securing cash runway into Q1 of FY26, the analyst tells investors in a research note. Optical genome mapping is also gaining traction at leading institutions, seeing real-world use, and generating publications, the firm adds.

HC Wainwright & Co.

Yi Chen

Strong Buy

Initiates

$10

2025-04-09

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2025-04-09

Initiates

Strong Buy

Reason

Scotiabank

Sung Ji Nam

Hold

Maintains

$1 → $4

2025-04-02

Reason

Scotiabank

Sung Ji Nam

Price Target

$1 → $4

2025-04-02

Maintains

Hold

Reason

Scotiabank raised the firm's price target on Bionano Genomics to $4 from $1 and keeps a Sector Perform rating on the shares. Despite the challenging macroeconomic environment in 2024, there were "bright spots" for the company, such as double-digit growth for Consumables and Software revenues, the analyst tells investors. The firm is favoring the sidelines until it has better visibility into the company's near- to medium-term growth potential.

Valuation Metrics

The current forward P/E ratio for Bionano Genomics Inc (BNGO.O) is -0.46, compared to its 5-year average forward P/E of -6.69. For a more detailed relative valuation and DCF analysis to assess Bionano Genomics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.69

Current PE

-0.46

Overvalued PE

3.69

Undervalued PE

-17.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.43

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

5.25

Undervalued EV/EBITDA

-18.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

22.97

Current PS

0.46

Overvalued PS

61.56

Undervalued PS

-15.62

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BNGO News & Events

Events Timeline

No data

News

3.5

2025-12-11Globenewswire

Bionano Genomics Showcases OGM Technology Enhancing Detection Capabilities

3.5

2025-12-11Newsfilter

Bionano Genomics Showcases OGM Technology for Enhanced Structural Variant Detection

7.5

2025-12-03Newsfilter

Bionano Laboratories Sees 47% Increase in 2026 CLFS for OGM Testing

People Also Watch

Frequently Asked Questions

What is Bionano Genomics Inc (BNGO) stock price today?

The current price of BNGO is 1.58 USD — it has decreased -1.25 % in the last trading day.

What is Bionano Genomics Inc (BNGO)'s business?

Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

What is the price predicton of BNGO Stock?

What is Bionano Genomics Inc (BNGO)'s revenue for the last quarter?

Bionano Genomics Inc revenue for the last quarter amounts to 7.37M USD, increased 21.31 % YoY.

What is Bionano Genomics Inc (BNGO)'s earnings per share (EPS) for the last quarter?

Bionano Genomics Inc. EPS for the last quarter amounts to -1.59 USD, decreased -94.86 % YoY.

What changes have occurred in the market's expectations for Bionano Genomics Inc (BNGO)'s fundamentals?

How many employees does Bionano Genomics Inc (BNGO). have?

Bionano Genomics Inc (BNGO) has 98 emplpoyees as of January 10 2026.

What is Bionano Genomics Inc (BNGO) market cap?

Today BNGO has the market capitalization of 16.08M USD.